mProX™ Human ALK Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1026	Magic™ Human ALK in Vitro Assay	Human		Kinase Assay
S01YF-1122-KX1027	Magic™ Human ALK[G1202R] in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

ALK

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

SH-SY5Y; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Neuroblastoma 3 and Neuroblastoma. Among its related pathways are Pluripotent stem cell differentiation pathway and Signaling by ALK in cancer

Gene ID

238

UniProt ID

Q9UM73

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

ALK receptor tyrosine kinase, a member of the receptor tyrosine kinase (RTK) family of proteins, is made using instructions derived from the ALK gene. The kinase binds to a comparable kinase after being activated at the cell surface to initiate the process. Phosphorylation is the process by which the kinase is marked with a phosphate group following dimerization. The kinase is activated by phosphorylation. Another protein in the cell can get a phosphate group from the activated kinase, activating it in the process. A signaling pathway's sequence of proteins carry on the activation. Numerous biological activities, including cell growth, division, and maturation, depend on these signaling pathways. The customized ALK stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Jacqueline

I highly recommend the ALK cell line for anyone working on membrane protein research. Feb 03 2023

chat Verified Customer

chat Jean

The ALK cell line proved to be an invaluable tool in my experiments. Its excellent performance and reproducibility greatly contributed to the success of my research project. Aug 30 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 ALK inhibitors inhibit or partially inhibit the proliferation of neuroblastoma cell lines harboring ALK aberrations.

Dose response curves of neuroblastoma cell lines with ALK mutations or increased expression subjected to ceritinib, crizotinib, alectinib, and PF06463922, four ALK inhibitors.

Ref: Wang, Hui Qin, et al. "Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models." Elife 6 (2017): e17137.

Pubmed: 28425916

DOI: 10.7554/eLife.17137

Research Highlights

When treating ALK-positive non-small-cell lung cancer (NSCLC), alexib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has demonstrated systemic and central nervous system (CNS) efficacy.
Peters, Solange, et al. "Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer." New England Journal of Medicine 377.9 (2017): 829-838.
Pubmed: 28586279 DOI: 10.1056/NEJMoa1704795

When crizotinib was no longer effective for treating patients with ALK-positive NSCLC, alexitab demonstrated clinical activity and was well tolerated. Therefore, individuals with ALK-positive illness who have not responded well to crizotinib may benefit from alectinib therapy.
Shaw, Alice T., et al. "Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial." The lancet oncology 17.2 (2016): 234-242.
Pubmed: 26708155 DOI: 10.1016/S1470-2045(15)00488-X